Register now for the RSNN Annual Workshop 2026!

Comparative evidence in a changing European landscape

The European medicines landscape is undergoing significant change. The implementation of the new EU Pharmaceutical Legislation and the EU HTA Regulation, together with an evolving geopolitical landscape, is reshaping how innovative medicines are developed, evaluated and made available to patients. These developments raise important questions about Europe’s future ambitions, competitiveness and collaboration in medicines development.

As the regulatory and HTA landscape evolves, expectations regarding comparative evidence are also changing. New responsibilities for European institutions, changing evidence requirements and increasing collaboration between stakeholders create both opportunities and challenges. At the same time, scientific advances and innovative study designs continue to expand the possibilities for generating evidence beyond traditional clinical trials.

Against this backdrop, the 2026 RSNN Annual Workshop brings together a diverse collection of speakers from different backgrounds such as regulatory authorities, HTA bodies, industry, academia, patients and others. The meeting offers a platform to explore how different stakeholders view these developments, where opportunities for collaboration exist, and which scientific, regulatory and practical challenges lie ahead.

Aim of the workshop

In this workshop, we will explore how the changing European regulatory and HTA landscape is influencing evidence generation, decision-making and collaboration across the medicine lifecycle. Questions that will be addressed during the workshop include:

• How are the new EU Pharmaceutical Legislation, the EU HTA Regulation and broader geopolitical developments shaping the future of medicines development in Europe?
• What opportunities and challenges do these developments create for regulators, HTA bodies, industry, healthcare professionals, payers and patients?
• What new roles, responsibilities and collaborations are emerging across the European medicines ecosystem?
• How can comparative evidence best support regulatory and HTA decision-making, particularly where evidence generation is challenging?
• Which scientific and methodological innovations can help address remaining evidence gaps?

Participants will gain insight into the changing European evidence landscape and how collaboration across stakeholder groups can contribute to more effective evidence generation, better-informed decision-making and timely patient access to innovative medicines.

Program and registration

Click here for the program of the workshop. Registration for the workshop is already possible, click here to register. We are looking forward to meeting you at the workshop!